RxDoctor Payments Data

Jihan Grant, MD

Pain Medicine · New York, NYNPI 1871884072

Payments from drug & device makers

$9,635in general payments, 2019–2025

Across 52 payments — averaging $185.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Amneal Pharmaceuticals LLC$3K
  • SPR Therapeutics, Inc$468
  • Teva Pharmaceuticals USA, Inc.$367
  • Impel Pharmaceuticals Inc.$332
  • Lundbeck LLC$193
  • plus $605 from 8 others

What the payments were for

  • Consulting fees$6,53068%
  • Travel & lodging$3384%
  • Food & beverage$2,76729%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,635 in reported general payments places this provider in the 80th percentile of 503 pain medicine providers in New York.

See all pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$211,719
Medicare patients
130
Services billed
24,620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm140$110,379
Nurtec OdtRimegepant Sulfate37$63,719
UbrelvyUbrogepant45$59,026
Aimovig AutoinjectorErenumab-Aooe19$23,239
Ajovy AutoinjectorFremanezumab-Vfrm18$17,429
QuliptaAtogepant13$17,272
Sumatriptan17$6,761
Sumatriptan Succinate50$3,402
Oxcarbazepine14$1,998
Eletriptan HbrEletriptan Hydrobromide15$1,495
Gabapentin97$1,408
Naproxen Sodium11$1,115
Diclofenac Sodium ErDiclofenac Sodium11$949
RizatriptanRizatriptan Benzoate35$924
Topiramate88$877

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$5,160$76,29858 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 503 pain medicine providers in New York.

Other pain medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →